The Mathilda and Terence Kennedy Institute of Rheumatology Trust

180 Therapeutics LP

The Kennedy Institute of Rheumatology

The Mathilda and Terence Kennedy Institute of Rheumatology

The Kennedy Trust for Rheumatology Research

Other

Marc Feldmann

Jagdeep Nanchahal

Ravinder Nath Maini

Glenn R Larsen

Fionula Mary Brennan

Mervyn Maze

Mario Cibelli

Daqing Ma

Michael Fertleman

Patrick William Gray

Martin John Turner

Brian Maurice John Foxwell

Raphael Mechoulam

Ruth Gallily

Yuti Chernajovsky

David Baker

Richard O Williams

Niccolo Terrando

Richard Neve

Anne-Marie Malfait

Michael J Elliott

John Leslie Turk

Brian Foxwell

Noccolo Terrando

The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

Method of treating early stage Dupuytren's disease

The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.

Methods for reducing post-operative cognitive dysfunction (POCD)

Method of treating dupuytren's disease using a pre-filled syringe

The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

Method of treating a localized fibrotic disorder using an IL-33 antagonist

Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate

Concomitant treatment of rheumatoid arthritis with anti-TNF-&#x3b1; antibodies and methotrexate

Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF-kB is disclosed. Examples of NF-kB inhibitors include IkB&#x3b1;, PSI, a nucleotide sequence encoding IkB&#x3b1; anti-sense nucleic acid encoding an NF-kB sequence, such as Rel B, and anti-NF-kB antibodies. Examples of NF-kB inducers include NIK, MEKK, IKK2, TFRRF2, and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF-kB, for example adenoviral vectors.

Activation and inhibition of the immune system

Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate

Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate

We describe (1) a method of enhancing antigen presentation, comprising the step of supplying to an antigen presenting cell such as a dendritic cell, or precursor cell, an inhibitor of Toll-related receptor (TRR) signalling and (2) a method of inhibiting antigen presentation, comprising the step of supplying to an antigen presenting cell such as a dendritic cell, or precursor cell, an enhancer of Toll-related receptor (TRR) signalling. The inhibitor of TRR signalling may be a dominant negative mutant of MyD88, for example MyD881pr.

Methods for enhancing antigen presentation

A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual.

Methods of preventing or treating thrombosis with tumor necrosis factor antagonists

A method of identifying a compound with efficacy in the treatment of chronic inflammatory disease by testing the compound for an ability to selectively inhibit the ability of Tcells to induce pro-inflammatory cytokine release from a monocyte is disclosed. The method includes pre-incubatin Tcells with a compound to be tested, optionally resuspending the Tcells in the absence of the test compound, co-culturing the Tcells with monocytes, and assaying for the production of pro-inflammatory cytokines by the monocytes. The Tcells are produced by incubating a population of T cells with one or more cytokines or the Tcells are isolated from synovial tissue. The Tcells have not been contacted with an anti-CD3 antibody. The ability to selectively inhibit cytokine release indicates that the compound has efficacy in the treatment of chronic inflammatory disease.

Method of identifying a compound that selectively inhibits cytokine-stimulated T cell induced production of TNF-alpha by monocytes

The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct. The invention also relates to a method of inhibiting the biological activity of TNF in a host comprising administering to the host an effective amount of a receptor molecule of the present invention. The invention further relates to receptor molecules which bind cytokines that bind to receptor molecules comprising more than one subunit.

Small molecular weight TNF receptor multimeric molecule

Growing community of inventors

London, United Kingdom

Marc Feldmann